US Edition
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
Summary by NJBIZ
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
The basics: Novo Nordisk cut ties with Hims & Hers over semaglutide concerns Company alleges illegal sales of unapproved Wegovy alternatives FDA limits compounding of GLP-1 drugs to patient-specific cases Novo Nordisk filed 120 lawsuits, invested $6.5B to scale production Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss dr…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
